These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 22777832)
1. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma. Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832 [TBL] [Abstract][Full Text] [Related]
2. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463 [TBL] [Abstract][Full Text] [Related]
3. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332 [TBL] [Abstract][Full Text] [Related]
4. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904 [TBL] [Abstract][Full Text] [Related]
5. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566 [TBL] [Abstract][Full Text] [Related]
6. Utility of Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732 [TBL] [Abstract][Full Text] [Related]
7. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma. Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024 [TBL] [Abstract][Full Text] [Related]
8. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma. Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198 [TBL] [Abstract][Full Text] [Related]
9. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577 [TBL] [Abstract][Full Text] [Related]
10. FDG PET using SUV Huang YC; Lu HI; Huang SC; Hsu CC; Chiu NT; Wang YM; Chiu YC; Li SH BMC Med Imaging; 2017 Jan; 17(1):1. PubMed ID: 28056868 [TBL] [Abstract][Full Text] [Related]
11. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? Monjazeb AM; Riedlinger G; Aklilu M; Geisinger KR; Mishra G; Isom S; Clark P; Levine EA; Blackstock AW J Clin Oncol; 2010 Nov; 28(31):4714-21. PubMed ID: 20876421 [TBL] [Abstract][Full Text] [Related]
13. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy. Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205 [TBL] [Abstract][Full Text] [Related]
14. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552 [TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607 [TBL] [Abstract][Full Text] [Related]
16. Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. Zhang H; Tan S; Chen W; Kligerman S; Kim G; D'Souza WD; Suntharalingam M; Lu W Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):195-203. PubMed ID: 24189128 [TBL] [Abstract][Full Text] [Related]
17. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Roedl JB; Halpern EF; Colen RR; Sahani DV; Fischman AJ; Blake MA Mol Imaging Biol; 2009; 11(1):54-60. PubMed ID: 18769974 [TBL] [Abstract][Full Text] [Related]
18. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Palie O; Michel P; Ménard JF; Rousseau C; Rio E; Bridji B; Benyoucef A; Meyer ME; Jalali K; Bardet S; M'vondo CM; Olivier P; Faure G; Itti E; Diana C; Houzard C; Mornex F; Di Fiore F; Vera P Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1345-55. PubMed ID: 23715903 [TBL] [Abstract][Full Text] [Related]
19. Xi M; Liao Z; Hofstetter WL; Komaki R; Ho L; Lin SH J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744 [TBL] [Abstract][Full Text] [Related]
20. To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan. Huang JW; Yeh HL; Hsu CP; Lu YY; Chuang CY; Lin JC; Lin JF; Chang CF J Chin Med Assoc; 2015 Apr; 78(4):229-34. PubMed ID: 25557468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]